BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 29445054)

  • 1. Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures.
    Yokoyama Y; Sasaki Y; Terasaki N; Kawataki T; Takekawa K; Iwase Y; Shimizu T; Sanoh S; Ohta S
    Biol Pharm Bull; 2018 May; 41(5):722-732. PubMed ID: 29445054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
    Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
    Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Hepatic HepaRG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP450 Activity/Metabolism and Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeutic Applications.
    Nelson LJ; Morgan K; Treskes P; Samuel K; Henderson CJ; LeBled C; Homer N; Grant MH; Hayes PC; Plevris JN
    Basic Clin Pharmacol Toxicol; 2017 Jan; 120(1):30-37. PubMed ID: 27285124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.
    Gerets HH; Tilmant K; Gerin B; Chanteux H; Depelchin BO; Dhalluin S; Atienzar FA
    Cell Biol Toxicol; 2012 Apr; 28(2):69-87. PubMed ID: 22258563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.
    Lübberstedt M; Müller-Vieira U; Mayer M; Biemel KM; Knöspel F; Knobeloch D; Nüssler AK; Gerlach JC; Zeilinger K
    J Pharmacol Toxicol Methods; 2011; 63(1):59-68. PubMed ID: 20460162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemically induced hepatotoxicity in human stem cell-induced hepatocytes compared with primary hepatocytes and HepG2.
    Kang SJ; Lee HM; Park YI; Yi H; Lee H; So B; Song JY; Kang HG
    Cell Biol Toxicol; 2016 Oct; 32(5):403-17. PubMed ID: 27287938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and HepaRG cells.
    Klein M; Thomas M; Hofmann U; Seehofer D; Damm G; Zanger UM
    Drug Metab Dispos; 2015 Feb; 43(2):273-83. PubMed ID: 25480923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems.
    Rodrigues RM; Heymans A; De Boe V; Sachinidis A; Chaudhari U; Govaere O; Roskams T; Vanhaecke T; Rogiers V; De Kock J
    Toxicol Lett; 2016 Jan; 240(1):50-9. PubMed ID: 26497421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
    Utkarsh D; Loretz C; Li AP
    Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline and genotoxic compound induced gene expression profiles in HepG2 and HepaRG compared to primary human hepatocytes.
    Jetten MJ; Kleinjans JC; Claessen SM; Chesné C; van Delft JH
    Toxicol In Vitro; 2013 Oct; 27(7):2031-40. PubMed ID: 23911569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.
    Hart SN; Li Y; Nakamoto K; Subileau EA; Steen D; Zhong XB
    Drug Metab Dispos; 2010 Jun; 38(6):988-94. PubMed ID: 20228232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytes.
    Cho YY; Jeong HU; Kim JH; Lee HS
    Drug Des Devel Ther; 2014; 8():2137-45. PubMed ID: 25395831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen.
    Li AP; Uzgare A; LaForge YS
    Chem Biol Interact; 2012 Jul; 199(1):1-8. PubMed ID: 22640811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies.
    Mueller D; Krämer L; Hoffmann E; Klein S; Noor F
    Toxicol In Vitro; 2014 Feb; 28(1):104-12. PubMed ID: 23850736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening.
    Wang Z; Luo X; Anene-Nzelu C; Yu Y; Hong X; Singh NH; Xia L; Liu S; Yu H
    J Appl Toxicol; 2015 Aug; 35(8):909-17. PubMed ID: 25512232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1.
    Li AP
    Chem Biol Interact; 2009 Apr; 179(1):4-8. PubMed ID: 18950609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.
    Aninat C; Piton A; Glaise D; Le Charpentier T; Langouët S; Morel F; Guguen-Guillouzo C; Guillouzo A
    Drug Metab Dispos; 2006 Jan; 34(1):75-83. PubMed ID: 16204462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential.
    Li AP; Lu C; Brent JA; Pham C; Fackett A; Ruegg CE; Silber PM
    Chem Biol Interact; 1999 Jun; 121(1):17-35. PubMed ID: 10418968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system.
    Darnell M; Ulvestad M; Ellis E; Weidolf L; Andersson TB
    J Pharmacol Exp Ther; 2012 Oct; 343(1):134-44. PubMed ID: 22776955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional HepaRG model as an attractive tool for toxicity testing.
    Leite SB; Wilk-Zasadna I; Zaldivar JM; Airola E; Reis-Fernandes MA; Mennecozzi M; Guguen-Guillouzo C; Chesne C; Guillou C; Alves PM; Coecke S
    Toxicol Sci; 2012 Nov; 130(1):106-16. PubMed ID: 22843569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.